Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain

Journal of Medical Economics

Volumn 12, Issue 3, 2009, Pages 192-202

  Wu, N ^a   Chen, S ^a   Boulanger, L ^a   Fraser, K ^a   Bledsoe, S L ^b   Zhao, Y ^b  

^a Abt Bio Pharma Solutions Inc   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Average daily dose; Compliance; Diabetic peripheral neuropathic pain; Duloxetine; Healthcare costs

Indexed keywords

AMFEBUTAMONE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DULOXETINE; GABAPENTIN; HYDROCODONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; AVERAGE DAILY DOSE; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIABETIC NEUROPATHY; DRUG DOSE REGIMEN; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEUROPATHIC PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DIABETIC NEPHROPATHIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIOPHENES; UNITED STATES;

EID: 75149184679     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903240559     Document Type: Article

References (35)

1. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81:S3-11
2. Boulton AJ. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9-15
3. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27;1458-1486
4. Boulton AJ, Vinik AI, Arezzo JC, et al. American Diabetes Association: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956-962
5. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;21;976-982
6. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156-162
7. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-25
8. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000;47:123-128
9. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-385
10. Currie CJ, Poole CD, Woehl A, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-2280
11. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-1522
12. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7:892-900 (Pubitemid 44854739)
13. Jude EB, Jacob K. Managing painful neuropathy in diabetes. Pol Arch Med Wewn 2008;118:260-261
14. Wu SC, Wrobel JS, Armstrong DG. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. Pain Med 2007;8:S33-42
15. Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med 2007;8:S27-32
16. Candrilli SD, Davis KL, Kan HJ, et al. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 2007;21:306-314
17. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672-679
18. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007;67:569-585
19. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053
20. American Diabetes Association (ADA) guideline. All About Diabetes. 2008;. Available at: http://www.diabetes.org/home.jsp
21. Diabetic peripheral neuropathic pain. Consensus guidelines for treatment. J Fam Pract 2006;(Suppl):3-19
22. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399-407
23. Cymbalta(R) [package insert]. Indianapolis, IN: Eli Lilly and Company, 2004
24. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-116
25. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-774
26. Bureau of Labor Statistics. Consumer Price Index, January 2008
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
28. McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman and Hall, 1989
29. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or count responses. Annu Rev Public Health 2007;28:95-111
30. Efron B, Tibhirani R. An Introduction to the Bootstrap. New York: Chapman and Hall, 1993
31. Gatti ME, Jacobson KL, Gazmararian JA, et al. Relationships between beliefs about medications and adherence. Am J Health Syst Pharm 2009;66:657-664
32. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-213
33. Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007;8:S50-62
34. Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 2003;19:516-521
35. Currie CJ, Poole CD, Woehl A, et al. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007;24:187-194